416 related articles for article (PubMed ID: 2195547)
1. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
Pearson L; Garcia J; Wu F; Modesti N; Nelson J; Gaynor R
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5079-83. PubMed ID: 2195547
[TBL] [Abstract][Full Text] [Related]
2. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of a potent HIV-2 Tat transdominant mutant protein.
Echetebu CO; Rhim H; Herrmann CH; Rice AP
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):655-64. PubMed ID: 8207644
[TBL] [Abstract][Full Text] [Related]
4. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.
Orsini MJ; Debouck CM
J Virol; 1996 Nov; 70(11):8055-63. PubMed ID: 8892930
[TBL] [Abstract][Full Text] [Related]
6. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
[TBL] [Abstract][Full Text] [Related]
7. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.
Kamine J; Subramanian T; Chinnadurai G
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8510-4. PubMed ID: 1924310
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins.
Fraisier C; Abraham DA; van Oijen M; Cunliffe V; Irvine A; Craig R; Dzierzak EA
Gene Ther; 1998 Jul; 5(7):946-54. PubMed ID: 9813666
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation in vitro by the human immunodeficiency virus type 1 Tat protein: evidence for specific interaction with a coactivator(s).
Song CZ; Loewenstein PM; Green M
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9357-61. PubMed ID: 7937769
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.
Arya SK
AIDS Res Hum Retroviruses; 1993 Sep; 9(9):839-48. PubMed ID: 8257633
[TBL] [Abstract][Full Text] [Related]
11. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA.
Delling U; Roy S; Sumner-Smith M; Barnett R; Reid L; Rosen CA; Sonenberg N
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6234-8. PubMed ID: 2068104
[TBL] [Abstract][Full Text] [Related]
12. RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator.
Graham GJ; Maio JJ
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5817-21. PubMed ID: 1696012
[TBL] [Abstract][Full Text] [Related]
13. A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.
Endo S; Kubota S; Siomi H; Adachi A; Oroszlan S; Maki M; Hatanaka M
Virus Genes; 1989 Nov; 3(2):99-110. PubMed ID: 2559542
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in the tat-responsive sequence.
Roy S; Parkin NT; Rosen C; Itovitch J; Sonenberg N
J Virol; 1990 Mar; 64(3):1402-6. PubMed ID: 2406460
[TBL] [Abstract][Full Text] [Related]
15. Conservative mutations in the putative metal-binding region of human immunodeficiency virus tat disrupt virus replication.
Sadaie MR; Mukhopadhyaya R; Benaissa ZN; Pavlakis GN; Wong-Staal F
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1257-63. PubMed ID: 2078407
[TBL] [Abstract][Full Text] [Related]
16. The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain.
Rappaport J; Lee SJ; Khalili K; Wong-Staal F
New Biol; 1989 Oct; 1(1):101-10. PubMed ID: 2562188
[TBL] [Abstract][Full Text] [Related]
17. Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins.
Tao J; Frankel AD
Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1571-5. PubMed ID: 8434019
[TBL] [Abstract][Full Text] [Related]
18. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.
Kuppuswamy M; Subramanian T; Srinivasan A; Chinnadurai G
Nucleic Acids Res; 1989 May; 17(9):3551-61. PubMed ID: 2542902
[TBL] [Abstract][Full Text] [Related]
19. The full-length Tat protein is required for TAR-independent, posttranscriptional trans activation of human immunodeficiency virus type 1 env gene expression.
Kim YS; Panganiban AT
J Virol; 1993 Jul; 67(7):3739-47. PubMed ID: 8510203
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat.
Mallon R; Borkowski J; Albin R; Pepitoni S; Schwartz J; Kieff E
J Virol; 1990 Dec; 64(12):6282-5. PubMed ID: 2173793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
